BD Primary Care #256095 Rapid Test Kit Promotion BD Veritor™ System Antigen Detection SARS-CoV-2 / Influenza A + B Direct Anterior Nasal Swab Sample 2 X 30 Tests COMBO KIT, SARS-COV-2/FLU A+B W/VERITOR D/S NEW ITEM - Shipments expected to begin around Sept 1, 2021 BD Triplex assay requires Veritor™ System firmware version 5.5 or greater; firmware version info is displayed on screen when turning on the analyzer or on the orange sticker if it is attached to the analyzer BD Veritor Plus System SARS/Flu (Triplex) Combo Promotional Kit - 2 X (256088) SARS-CoV-2/Influenza A + B Rapid Test Kit and (256066) BD Veritor Plus Analyzer BD Veritor System for Rapid Detection of SARS-CoV-2 and Flu A+B is For use under an Emergency Use Authorization only: https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-antigen-diagnostic-tests-sars-cov-2 This test is authorized for use at the Point of Care (POC), i.e., i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation Laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet the requirements to perform moderate, high, or waived complexity tests This product has been authorized only for the detection of proteins from SARS-CoV-2, influenza A and influenza B, not for any other viruses or pathogens The test is intended to be used with direct nasal swabs and is not validated for use with swabs in viral transport media Kit configured for testing anterior nasal swab samples freshly collected, processed, and dispensed directly onto assay test device Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status Positive results do not rule out bacterial infection or co-infection with other viruses Laboratories within the United States and its territories are required to report all SARS-CoV-2 results to the appropriate public health authorities Negative results should be treated as presumptive, do not rule out either Influenza or SARS-CoV-2, and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions Negative results should be considered in the context of a patient’s recent exposures, history and the presence of clinical signs and symptoms consistent with one of these infections Negative results for SARS-CoV-2 should be confirmed with a molecular assay, if necessary, for patient management The BD Veritor System for Rapid Detection of SARS-CoV-2 & Flu A+B is intended for use in point of care settings by trained healthcare professionals or other users specifically instructed in the use of BD Veritor Systems and proper infection control procedures Time to result: 15 minutes, test device can be read at 15 minutes but no later than 20 minute Each test kit contains: (30) Single Use Test Devices, (30) Single Use Reaction Tubes with 400 µL Reagent, (30) Sterile Single Use Sampling Swabs, 1 Positive SARS-CoV-2 Control Swab, 1 Positive Flu A Control Swab, 1 Positive Flu B Control Swab, (3) Paperboard Tube Stands, IFU, Quick Ref Card, and Nasal Sampling Guide Manufacturer # 256095 Brand BD Veritor™ System Manufacturer BD Primary Care Country of Origin Unknown Application Rapid Test Kit Promotion Contents 1 (2) Test Kits SARS-CoV-2 / Influenza A + B (30 Test each Kit), BD Veritor™ Plus Analyzer For Use With For use with the BD Veritor™ Plus Analyzer running Firmware version 5.50 or late Number of Tests 2 X 30 Tests Product Dating Acceptable Dating: we will ship >= 90 days Reading Type Machine Read Sample Type Direct Anterior Nasal Swab Sample Test Format Test Device Format Test Method Rapid Chromatographic Digital Immunoassay Test Name SARS-CoV-2 / Influenza A + B Test Type Antigen Detection Time to Results 15 Minute Results UNSPSC Code 41116205
More Information
